COX-2 Safety Will Be Discussed By FDA Advisory Committee In Early 2005

FDA will hold an advisory committee in early 2005 to discuss the cardiovascular safety profile of COX-2 inhibitors, Acting Deputy Commissioner of Operations Janet Woodcock, MD, said at an American College of Rheumatology meeting Oct. 18 in San Antonio

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet